ContractWarrant Agreement • March 12th, 2020 • Alzamend Neuro, Inc. • Pharmaceutical preparations • New York
THIS WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR QUALIFIED UNDER ANY STATE OR FOREIGN SECURITIES LAWS AND MAY NOT BE OFFERED FOR SALE, SOLD, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED OR ASSIGNED UNLESS (I) A REGISTRATION STATEMENT COVERING SUCH SHARES IS EFFECTIVE UNDER THE SECURITIES ACT AND IS QUALIFIED UNDER APPLICABLE STATE AND FOREIGN LAW OR (II) THE TRANSACTION IS EXEMPT FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS UNDER THE SECURITIES ACT AND THE QUALIFICATION REQUIREMENTS UNDER APPLICABLE STATE AND FOREIGN LAW AND, IF THE CORPORATION REQUESTS, AN OPINION SATISFACTORY TO THE CORPORATION TO SUCH EFFECT HAS BEEN RENDERED BY COUNSEL.
SUBSCRIPTION AGREEMENT – NOTICE TO INVESTORSSubscription Agreement • March 12th, 2020 • Alzamend Neuro, Inc. • Pharmaceutical preparations • New York
THIS INVESTMENT INVOLVES A HIGH DEGREE OF RISK. THIS INVESTMENT IS SUITABLE ONLY FOR PERSONS WHO CAN BEAR THE ECONOMIC RISK FOR AN INDEFINITE PERIOD OF TIME AND WHO CAN AFFORD TO LOSE THEIR ENTIRE INVESTMENT. FURTHERMORE, INVESTORS MUST UNDERSTAND THAT SUCH INVESTMENT IS ILLIQUID AND IS EXPECTED TO CONTINUE TO BE ILLIQUID FOR AN INDEFINITE PERIOD OF TIME. NO PUBLIC MARKET EXISTS FOR THE SECURITIES.
CONSULTING AGREEMENTConsulting Agreement • March 12th, 2020 • Alzamend Neuro, Inc. • Pharmaceutical preparations • New York
This Consulting Agreement (the “Agreement”) is made as of June 28, 2017 (“Effective Date”) between Spartan Capital Securities, LLC (the “Consultant”) and Alzamend Neuro, Inc., a Delaware corporation (the “Company”). The Company and the Consultant are collectively herein referred to as the “Parties.”
Dear Mr. Stephan Jackman, This letter is an amendment to the CEO Offer Letter dated October 27, 2018 which detailed terms of your employment agreement. As of this date, you confirm your continued willingness to serve as the Chief Executive Officer...Ceo Offer Letter • March 12th, 2020 • Alzamend Neuro, Inc. • Pharmaceutical preparations
• Three million options (3,000,000) shall vest ratably over 48 months beginning with the first month after the grant date. • One million options (1,000,000) shall vest upon approval of a NDA for LiProSal by the FDA within 36 months from November 1, 2018. • One million options (1,000,000) shall vest upon approval of a NDA for CAO2W by the FDA within 48 months from November 1, 2018.
STOCK PLEDGE AGREEMENTStock Pledge Agreement • March 12th, 2020 • Alzamend Neuro, Inc. • Pharmaceutical preparations • New York
This STOCK PLEDGE AGREEMENT (“Agreement”) is made and entered as of this ____ day of June 11, 2019 by and between Ault Life Sciences Fund, LLC, a Delaware limited liability company maintaining a business address at 201 Shipyard Way, Suite E, Newport Beach California 92663 (the “Pledgor”), and Alzamend Neuro, Inc., a Delaware corporation with offices located at 3802 Spectrum Boulevard, Suite 112C, Tampa, Florida 33612, the intended beneficiary of the rights, privileges and benefits of this Stock Pledge Agreement (the “Beneficiary”).
